<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605174</url>
  </required_header>
  <id_info>
    <org_study_id>16889</org_study_id>
    <secondary_id>H8H-CD-LAHK</secondary_id>
    <secondary_id>2015-005689-40</secondary_id>
    <secondary_id>COL MIG-302</secondary_id>
    <nct_id>NCT02605174</nct_id>
  </id_info>
  <brief_title>Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine</brief_title>
  <acronym>SPARTAN</acronym>
  <official_title>A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CoLucid Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized, double-blind, placebo-controlled study in participants with
      disabling migraine (Migraine Disability Assessment (MIDAS) score â‰¥ 11).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be asked to treat a migraine attack with study drug on an outpatient basis.
      Participants will be provided with a dosing card containing a dose for initial treatment and
      a second dose to be used for rescue or recurrence of migraine. Each participant's study
      participation will consist of screening (Visit 1) with a telephone contact within 7 days to
      confirm eligibility, a Treatment Period of up to 8 weeks, and End-of-Study (EoS) (Visit 2)
      within one week (7 days) of treating a single migraine attack. The total time on study is
      approximately up to 11 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Headache Pain Free at 2 Hours Post Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Headache Relief</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Headache Recurrence</measure>
    <time_frame>From 2 Hours Post Dose Up to 48 Hours</time_frame>
    <description>The number of participants with headache recurrence (moderate or severe at baseline which became pain-free at 2 hours post dose and worsened again up to 48 hours post dose)</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Use of Rescue Medication</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants who used rescue medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Use of Rescue Medication</measure>
    <time_frame>From 2 Hours Post Dose Up to 24 Hours</time_frame>
    <description>The percentage of participants who used rescue medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Use of Rescue Medication</measure>
    <time_frame>From 24 Post Dose Up to 48 Hours</time_frame>
    <description>The percentage of participants who used rescue medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Nausea Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participant without nausea.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Phonophobia Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants without phonophobia.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Photophobia Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants without photophobia.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Resource Utilization</measure>
    <time_frame>6 Months Prior to Enrolling in Study to End of Study (Up to 11 Weeks) Within 7 Days of Treating a Single Migraine Attack</time_frame>
    <description>Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Treatment Emergent Events</measure>
    <time_frame>From Baseline Up to End of Study (Up to 11 Weeks)</time_frame>
    <description>Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3005</enrollment>
  <condition>Migraine With or Without Aura</condition>
  <arm_group>
    <arm_group_label>Lasmiditan 50 milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 50 mg</intervention_name>
    <description>One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)</description>
    <arm_group_label>Lasmiditan 50 milligram (mg)</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 100 mg</intervention_name>
    <description>One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)</description>
    <arm_group_label>Lasmiditan 100 mg</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 200 mg</intervention_name>
    <description>One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)</description>
    <arm_group_label>Lasmiditan 200 mg</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two placebo tablets to match lasmiditan doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to give written informed consent and authorize HIPAA.

          -  Participants with migraine with or without aura fulfilling the International Headache
             Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification
             (ICHD) 2004).

          -  History of disabling migraine for at least 1 year.

          -  Migraine Disability Association (MIDAS) score â‰¥11.

          -  Migraine onset before the age of 50 years.

          -  History of 3 - 8 migraine attacks per month (&lt; 15 headache days per month).

          -  Male or female, aged 18 years or above.

          -  Females of child-bearing potential must be using or willing to use a highly effective
             form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD),
             abstinence or vasectomized partner).

          -  Able and willing to complete an electronic diary to record details of the migraine
             attack treated with study drug.

        Exclusion Criteria:

          -  Any medical condition or clinical laboratory test which in the judgment of the
             Investigator makes the participant unsuitable for the study.

          -  Pregnant or breast-feeding women.

          -  Women of child-bearing potential not using or not willing to use highly effective
             contraception.

          -  Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets,
             or any sensitivity to lasmiditan.

          -  History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the
             participant at increased risk of seizures.

          -  History of recurrent dizziness and/or vertigo including benign paroxysmal positional
             vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular
             disorders.

          -  History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or
             neuropathy).

          -  History within the previous three years or current evidence of abuse of any drug,
             prescription or illicit, or alcohol.

          -  History of orthostatic hypotension with syncope.

          -  Significant renal or hepatic impairment.

          -  Participant is at imminent risk of suicide (positive response to question 4 or 5) on
             the Columbia-Suicide Severity Rating Scale (C-SSRS) or had a suicide attempt within
             six months prior to screening.

          -  Previous participation in this clinical trial.

          -  Participation in any clinical trial of an experimental drug or device in the previous
             30 days.

          -  Known Hepatitis B or C or HIV infection.

          -  History, within past 12 months, of chronic migraine or other forms of primary or
             secondary chronic headache disorder (e.g. hemicranias continua, medication overuse
             headache) where headache frequency is â‰¥15 headache days per month.

          -  Use of more than 3 doses per month of either opiates or barbiturates.

          -  Initiation of or a change in concomitant medication to reduce the frequency of
             migraine episodes within three (3) months prior to Screening/Visit 1.

          -  Participants who are employees of the sponsor.

          -  Relatives of, or staff directly reporting to, the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Affiliated Research Center, Inc. - ARC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>21st Century Neurology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Center of Southern California</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute, Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Valley Research</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Clinical Research Center</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Foundation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lytle and Weiss, PLLC dba Clinical Trials of the Rockies</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Care</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Clinical Reseach, LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Core Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research West Coast</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research &amp; Health Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veritas Research Corporation</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floriday Medical Center and Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmony Clinical Research Inc.</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center, LLC</name>
      <address>
        <city>Royal Palm Beach</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research, Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Trials, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Clinic, LLC</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc.</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goldpoint Clinical Research, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Neurology, P.S.C.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Integrity, LLC.</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research, Inc.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Clinical Research, LLC</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Head Pain &amp; Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adirondack Medical Research Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio Behavioral Health</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville Neurology Specialists, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Cary, LLC</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVA Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Oregon) Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners in Clinical Research</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BTC of Lincoln Research,LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research, Inc.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group, P.C.</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Neuroscience Group</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protenium Clinical Research</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development, LLC</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc.- Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. - Jordan River Family Medicine</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research, LLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists Inc</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <results_first_submitted>June 28, 2018</results_first_submitted>
  <results_first_submitted_qc>June 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2018</results_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02605174/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02605174/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomly assigned to 1 of 7 sequences and received lasmiditan 50 mg (L50 mg), lasmiditan 100 mg (L100 mg) or lasmiditan 200 mg (L200 mg) or placebo (P) for the first dose and the second dose, if needed for rescue or recurrence of migraine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lasmiditan 50 Milligram (mg)/Lasmiditan 50 mg</title>
          <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. An optional second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="P2">
          <title>Lasmiditan 50 mg/Placebo</title>
          <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. An optional placebo second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="P3">
          <title>Lasmiditan 100 mg/Lasmiditan 100 mg</title>
          <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. An optional second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="P4">
          <title>Lasmitidan 100 mg/Placebo</title>
          <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. An optional placebo second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="P5">
          <title>Lasmiditan 200 mg/Lasmiditan 200 mg</title>
          <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. An optional second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="P6">
          <title>Lasmitidan 200 mg/Placebo</title>
          <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. An optional placebo second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="P7">
          <title>Placebo/Placebo</title>
          <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, daily for acute treatment of migraine. An optional second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
                <participants group_id="P2" count="249"/>
                <participants group_id="P3" count="502"/>
                <participants group_id="P4" count="252"/>
                <participants group_id="P5" count="501"/>
                <participants group_id="P6" count="249"/>
                <participants group_id="P7" count="751"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="423"/>
                <participants group_id="P4" count="212"/>
                <participants group_id="P5" count="434"/>
                <participants group_id="P6" count="215"/>
                <participants group_id="P7" count="645"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Optional 2nd Dose</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="177"/>
                <participants group_id="P4" count="83"/>
                <participants group_id="P5" count="144"/>
                <participants group_id="P6" count="74"/>
                <participants group_id="P7" count="361"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="426"/>
                <participants group_id="P4" count="216"/>
                <participants group_id="P5" count="448"/>
                <participants group_id="P6" count="217"/>
                <participants group_id="P7" count="662"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="32"/>
                <participants group_id="P7" count="89"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization Failure</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Lasmiditan 50 mg</title>
          <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="B2">
          <title>Lasmiditan 100 mg</title>
          <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="B3">
          <title>Lasmiditan 200 mg</title>
          <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="654"/>
            <count group_id="B2" value="635"/>
            <count group_id="B3" value="649"/>
            <count group_id="B4" value="645"/>
            <count group_id="B5" value="2583"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="13.20"/>
                    <measurement group_id="B2" value="43.4" spread="12.59"/>
                    <measurement group_id="B3" value="41.8" spread="12.40"/>
                    <measurement group_id="B4" value="42.6" spread="12.90"/>
                    <measurement group_id="B5" value="42.7" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="554"/>
                    <measurement group_id="B2" value="539"/>
                    <measurement group_id="B3" value="536"/>
                    <measurement group_id="B4" value="545"/>
                    <measurement group_id="B5" value="2174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="110"/>
                    <measurement group_id="B5" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="524"/>
                    <measurement group_id="B2" value="509"/>
                    <measurement group_id="B3" value="522"/>
                    <measurement group_id="B4" value="516"/>
                    <measurement group_id="B5" value="2071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="124"/>
                    <measurement group_id="B5" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="515"/>
                    <measurement group_id="B2" value="493"/>
                    <measurement group_id="B3" value="511"/>
                    <measurement group_id="B4" value="518"/>
                    <measurement group_id="B5" value="2037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Participants in each region are those who were randomized to each arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="625"/>
                    <measurement group_id="B2" value="627"/>
                    <measurement group_id="B3" value="626"/>
                    <measurement group_id="B4" value="626"/>
                    <measurement group_id="B5" value="2504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Headache Pain Free at 2 Hours Post Dose</title>
        <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable headache pain free data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Headache Pain Free at 2 Hours Post Dose</title>
          <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable headache pain free data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="532"/>
                <count group_id="O3" value="528"/>
                <count group_id="O4" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="31.4"/>
                    <measurement group_id="O3" value="38.8"/>
                    <measurement group_id="O4" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free</title>
        <description>The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable MBS data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free</title>
          <description>The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable MBS data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="483"/>
                <count group_id="O4" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8"/>
                    <measurement group_id="O2" value="44.2"/>
                    <measurement group_id="O3" value="48.7"/>
                    <measurement group_id="O4" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Headache Relief</title>
        <description>The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable headache relief data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Headache Relief</title>
          <description>The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable headache relief data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="571"/>
                <count group_id="O3" value="565"/>
                <count group_id="O4" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="64.8"/>
                    <measurement group_id="O3" value="65.0"/>
                    <measurement group_id="O4" value="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Headache Recurrence</title>
        <description>The number of participants with headache recurrence (moderate or severe at baseline which became pain-free at 2 hours post dose and worsened again up to 48 hours post dose)</description>
        <time_frame>From 2 Hours Post Dose Up to 48 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable headache recurrence data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Headache Recurrence</title>
          <description>The number of participants with headache recurrence (moderate or severe at baseline which became pain-free at 2 hours post dose and worsened again up to 48 hours post dose)</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable headache recurrence data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Use of Rescue Medication</title>
        <description>The percentage of participants who used rescue medication.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Use of Rescue Medication</title>
          <description>The percentage of participants who used rescue medication.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="571"/>
                <count group_id="O3" value="565"/>
                <count group_id="O4" value="576"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="26.4"/>
                    <measurement group_id="O3" value="18.9"/>
                    <measurement group_id="O4" value="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Use of Rescue Medication</title>
        <description>The percentage of participants who used rescue medication.</description>
        <time_frame>From 2 Hours Post Dose Up to 24 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Use of Rescue Medication</title>
          <description>The percentage of participants who used rescue medication.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="571"/>
                <count group_id="O3" value="565"/>
                <count group_id="O4" value="576"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="7.4"/>
                    <measurement group_id="O4" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.917</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.456</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Use of Rescue Medication</title>
        <description>The percentage of participants who used rescue medication.</description>
        <time_frame>From 24 Post Dose Up to 48 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Use of Rescue Medication</title>
          <description>The percentage of participants who used rescue medication.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="571"/>
                <count group_id="O3" value="565"/>
                <count group_id="O4" value="576"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Nausea Free</title>
        <description>The percentage of participant without nausea.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable nausea free data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Nausea Free</title>
          <description>The percentage of participant without nausea.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable nausea free data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="571"/>
                <count group_id="O3" value="565"/>
                <count group_id="O4" value="576"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7"/>
                    <measurement group_id="O2" value="71.8"/>
                    <measurement group_id="O3" value="70.4"/>
                    <measurement group_id="O4" value="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.522</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.622</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.992</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Phonophobia Free</title>
        <description>The percentage of participants without phonophobia.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable phonophobia free data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Phonophobia Free</title>
          <description>The percentage of participants without phonophobia.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable phonophobia free data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="571"/>
                <count group_id="O3" value="565"/>
                <count group_id="O4" value="576"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="64.8"/>
                    <measurement group_id="O3" value="65.3"/>
                    <measurement group_id="O4" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Photophobia Free</title>
        <description>The percentage of participants without photophobia.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable photophobia free data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Photophobia Free</title>
          <description>The percentage of participants without photophobia.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable photophobia free data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="571"/>
                <count group_id="O3" value="565"/>
                <count group_id="O4" value="576"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="56.4"/>
                    <measurement group_id="O3" value="58.2"/>
                    <measurement group_id="O4" value="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Resource Utilization</title>
        <description>Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study</description>
        <time_frame>6 Months Prior to Enrolling in Study to End of Study (Up to 11 Weeks) Within 7 Days of Treating a Single Migraine Attack</time_frame>
        <population>All randomized participants who had received at least one dose of study drug and had evaluable resource utilization data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg/Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. An optional Lasmitidan 50 mg second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 50 mg/Placebo</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. An optional placebo second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 100 mg/Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Lasmiditan 100 mg/Placebo</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine. Then, participants were assigned to placebo.</description>
          </group>
          <group group_id="O5">
            <title>Lasmiditan 200 mg/Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine. Then, participants were assigned to Lasmiditan 200 mg.</description>
          </group>
          <group group_id="O6">
            <title>Lasmiditan 200 mg/Placebo</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine. Then, participants were assigned to placebo.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Resource Utilization</title>
          <description>Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study</description>
          <population>All randomized participants who had received at least one dose of study drug and had evaluable resource utilization data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="423"/>
                <count group_id="O4" value="212"/>
                <count group_id="O5" value="434"/>
                <count group_id="O6" value="215"/>
                <count group_id="O7" value="645"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months prior to enrolling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="2.4"/>
                    <measurement group_id="O5" value="3.2"/>
                    <measurement group_id="O6" value="3.3"/>
                    <measurement group_id="O7" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During time of study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0.9"/>
                    <measurement group_id="O6" value="0.5"/>
                    <measurement group_id="O7" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Treatment Emergent Events</title>
        <description>Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section</description>
        <time_frame>From Baseline Up to End of Study (Up to 11 Weeks)</time_frame>
        <population>All randomized participants who had received at least one dose of study drug. Results are displayed by the first dose taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasmiditan 50 mg</title>
            <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. An optional Lasmitidan 50 mg second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>Lasmiditan 100 mg</title>
            <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. An optional placebo second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>Lasmiditan 200 mg</title>
            <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Events</title>
          <description>Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section</description>
          <population>All randomized participants who had received at least one dose of study drug. Results are displayed by the first dose taken.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="654"/>
                <count group_id="O2" value="635"/>
                <count group_id="O3" value="649"/>
                <count group_id="O4" value="645"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="253"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline Up to End of Study (Up to 11 Weeks)</time_frame>
      <desc>The safety population includes all participants who received at least one dose of study drug and the optional second dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lasmiditan 50 mg/Lasmiditan 50 mg</title>
          <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. An optional Lasmitidan 50 mg second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="E2">
          <title>Lasmiditan 50 mg/Placebo</title>
          <description>Lasmiditan 50 mg was administered orally, once for acute treatment of migraine. An optional placebo second dose was administered between 2 and 24 hours for rescue or recurrence of migraine</description>
        </group>
        <group group_id="E3">
          <title>Lasmiditan 100 mg/Lasmiditan 100 mg</title>
          <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. An optional Lasmitidan 100 mg second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="E4">
          <title>Lasmiditan 100 mg/Placebo</title>
          <description>Lasmiditan 100 mg was administered orally, once for acute treatment of migraine. An optional placebo second dose was administered between 2 and 24 hours for rescue or recurrence of migraine</description>
        </group>
        <group group_id="E5">
          <title>Lasmiditan 200 mg/Lasmiditan 200 mg</title>
          <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. An optional Lasmitidan 200 mg second dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
        </group>
        <group group_id="E6">
          <title>Lasmiditan 200 mg/Placebo</title>
          <description>Lasmiditan 200 mg was administered orally, once for acute treatment of migraine. An optional placebo second dose was administered between 2 and 24 hours for rescue or recurrence of migraine</description>
        </group>
        <group group_id="E7">
          <title>Placebo/Placebo</title>
          <description>Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered within 24 hours for rescue or recurrence of migraine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somatisation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="149" subjects_at_risk="423"/>
                <counts group_id="E4" subjects_affected="94" subjects_at_risk="212"/>
                <counts group_id="E5" subjects_affected="177" subjects_at_risk="435"/>
                <counts group_id="E6" subjects_affected="87" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="80" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Chromatopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="429"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="225"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="423"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="212"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="435"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="435"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="429"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="225"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="423"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E5" events="21" subjects_affected="21" subjects_at_risk="435"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Sense of oppression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Pulse pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="423"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Clumsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="429"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E3" events="84" subjects_affected="77" subjects_at_risk="423"/>
                <counts group_id="E4" events="45" subjects_affected="45" subjects_at_risk="212"/>
                <counts group_id="E5" events="94" subjects_affected="89" subjects_at_risk="435"/>
                <counts group_id="E6" events="33" subjects_affected="33" subjects_at_risk="217"/>
                <counts group_id="E7" events="17" subjects_affected="16" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Facial spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Formication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="423"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="423"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="435"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="429"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="225"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="423"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="212"/>
                <counts group_id="E5" events="34" subjects_affected="30" subjects_at_risk="435"/>
                <counts group_id="E6" events="14" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="429"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="225"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="423"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="212"/>
                <counts group_id="E5" events="36" subjects_affected="34" subjects_at_risk="435"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E7" events="13" subjects_affected="13" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Vertigo cns origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Depersonalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hypervigilance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Panic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Sleep terror</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Nasal odour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="646"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="646"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

